According to Reuters.com it was put up for sale a month ago and attracted interest from a number of large pharmaceutical companies, including Novartis and Johnson & Johnson. -- Drugmaking giant GlaxoSmithKline (GSK) has agreed to buy independent U.S. skincare specialist Stiefel Laboratories for up to $3.6 billion. The new business will have a broad portfolio of dermatology products including Stiefel's leading brands: Duac, for acne, Olux E for dermatitis and Soriatane for the treatment of severe psoriasis. GSK's existing prescription dermatological products will be combined with Stiefel's and the new specialist global business will operate under the Stiefel identity within the GSK Group. "The addition of Stiefel's broad portfolio will provide immediate new revenue flows to GSK with significant opportunities to enhance growth through leveraging our existing global commercial infrastructure and manufacturing capability.